FDA WARNING_LETTER - Resurrection Vapor LLC - April 12, 2022

On April 1, 2022, the FDA issued a Warning Letter to Jeffrey Hasley of Resurrection Vapor, following a review of their website, https://resurrectionvapor.com. The FDA determined that e-liquid products, specifically "Purple Pixie Dust" and "Ruby Slippers," were manufactured and offered for sale or distribution in the United States.

These e-liquid products are classified as "new tobacco products" under section 201(rr) of the FD&C Act because they are derived from tobacco and intended for human consumption, and were not commercially marketed in the U.S. as of February 15, 2007. The FDA found that these products lacked the required premarket authorization order under section 910(c)(1)(A)(i) of the FD&C Act, rendering them adulterated under section 902(6)(A) and misbranded under section 903(a)(6) of the FD&C Act.

Resurrection Vapor is a registered manufacturer with 550 products listed with the FDA. Their Premarket Tobacco Product Application (PMTA) STN PM0003677, covering 223 products, received a Refuse to File determination on August 16, 2021. The FDA emphasizes that all new tobacco products marketed without statutory premarket authorization are unlawful and subject to enforcement actions, including